Metsera has raised $510.0M in total across 2 funding rounds.
Metsera's investors include ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group, Venrock.
Metsera is a clinical-stage biopharmaceutical company developing next-generation therapies for obesity and metabolic diseases, focusing on oral and injectable Nutrient Stimulated Hormone (NuSH) programs targeting incretin, non-incretin, and combination therapies.[2][3] Founded in 2022 and based in New York City, it addresses limitations of current weight loss drugs like Wegovy and Mounjaro—such as muscle loss, side effects, frequent dosing, and scalability—by engineering candidates with improved potency, durability, combinability, and tolerability to serve patients needing better efficacy and convenience.[1][2][3] The company raised $290 million initially from Arch Venture Partners and Population Health Partners, advancing a broad pipeline including two therapies in clinical testing and others nearing trials, before entering a definitive acquisition agreement with Pfizer to leverage its global capabilities.[1][2]
Metsera was founded in 2022 by Clive Meanwell (initial CEO) and a team including Whit Bernard (Co-Founder and current CEO), backed by Arch Venture Partners and Population Health Partners, which Meanwell chairs.[1][2] Meanwell, with support from Arch managing director Kristina Burow, assembled an investor syndicate to raise $290 million upfront—an unusually large sum for a stealth biotech—and scoured globally for assets, acquiring U.K.-based Zihipp for a library of gut hormone-targeting prospects and licensing oral peptide technology from Korean firm D&D Pharmatech.[1] This "portfolio strategy" emerged to fast-track "second, third, or fourth generation" obesity drugs, building on 20+ years of peptide expertise to in-license and invent therapies amid surging demand for GLP-1 alternatives.[1][2][4] Early traction included rapid clinical advancements, with two programs in testing by launch and a Pfizer acquisition announced to scale development.[2]
Metsera rides the explosive GLP-1/obesity drug wave, where market leaders like Novo Nordisk and Eli Lilly dominate but face scalability limits, side effects, and needs for next-gen options amid a global crisis affecting hundreds of millions.[1][2] Timing is ideal post-2022 surge in Wegovy/Mounjaro demand, with market forces like aging populations, rising metabolic diseases, and oral/injectable combo demand favoring agile biotechs; Metsera's portfolio strategy differentiates from "first-generation" players by targeting multi-hormone approaches and non-incretins.[1][3] It influences the ecosystem by accelerating innovation—via acquisitions like Zihipp and tech like oral peptides—pressuring incumbents and enabling combinations, while its Pfizer deal exemplifies Big Pharma's strategy to consolidate promising assets in a $100B+ market.[2]
Pfizer's acquisition positions Metsera's pipeline for rapid late-stage trials and global launch, potentially delivering once-monthly injectables and orals that surpass current leaders in efficacy and convenience.[2][3] Trends like AI-driven peptide design, combo therapies, and metabolic disease expansion (e.g., cardiometabolic) will shape its path, with regulatory nods (e.g., BLAs) and manufacturing scale unlocking mass access.[2][3] Influence evolves from nimble startup to Pfizer-backed powerhouse, redefining obesity care and inspiring portfolio plays in biotech. This builds on Metsera's launch promise: a richly funded challenger now primed to transform a godsend market into an accessible revolution.[1][2]
Metsera has raised $510.0M across 2 funding rounds. Most recently, it raised $220.0M Series B in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $220.0M Series B | ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group, Venrock | |
| Apr 1, 2024 | $290.0M Series A | ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group |
